1. Home
  2. RXO vs WVE Comparison

RXO vs WVE Comparison

Compare RXO & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RXO Inc.

RXO

RXO Inc.

HOLD

Current Price

$13.91

Market Cap

2.2B

Sector

N/A

ML Signal

HOLD

Logo Wave Life Sciences Ltd.

WVE

Wave Life Sciences Ltd.

HOLD

Current Price

$6.39

Market Cap

2.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RXO
WVE
Founded
2022
2012
Country
United States
Singapore
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
2.4B
IPO Year
2022
2015

Fundamental Metrics

Financial Performance
Metric
RXO
WVE
Price
$13.91
$6.39
Analyst Decision
Hold
Strong Buy
Analyst Count
15
16
Target Price
$16.38
$31.19
AVG Volume (30 Days)
1.7M
4.2M
Earning Date
05-06-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
72.81
N/A
EPS
N/A
N/A
Revenue
$5,742,000,000.00
$3,704,000.00
Revenue This Year
$0.78
$0.34
Revenue Next Year
$6.58
$83.30
P/E Ratio
N/A
N/A
Revenue Growth
26.20
149.43
52 Week Low
$10.43
$5.02
52 Week High
$19.65
$21.73

Technical Indicators

Market Signals
Indicator
RXO
WVE
Relative Strength Index (RSI) 48.69 21.83
Support Level $12.01 N/A
Resistance Level $16.62 $8.15
Average True Range (ATR) 0.81 0.78
MACD 0.15 -0.65
Stochastic Oscillator 68.75 14.23

Price Performance

Historical Comparison
RXO
WVE

About RXO RXO Inc.

RXO Inc is a brokered transportation platform defined by cutting-edge technology and a nimble, asset-light business model, with the component being core truck brokerage business. Its operations also include three asset-light, brokered transportation services, all of which complement its truck brokerage business: managed transportation, last mile and freight forwarding. The company operates into one reportable segment. The operates within the transportation industry and in the same geography North America.

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Share on Social Networks: